Compare WEST & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEST | VSTM |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | United States | United States |
| Employees | 1393 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.6M | 470.7M |
| IPO Year | N/A | 2011 |
| Metric | WEST | VSTM |
|---|---|---|
| Price | $5.11 | $6.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $8.00 | ★ $16.50 |
| AVG Volume (30 Days) | 289.9K | ★ 2.1M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | $11.19 | $282.64 |
| Revenue Next Year | $10.74 | $72.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $3.59 | $4.01 |
| 52 Week High | $7.92 | $11.25 |
| Indicator | WEST | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 65.80 | 61.25 |
| Support Level | $4.49 | $6.01 |
| Resistance Level | $5.20 | $6.79 |
| Average True Range (ATR) | 0.23 | 0.40 |
| MACD | 0.09 | 0.13 |
| Stochastic Oscillator | 94.34 | 85.21 |
Westrock Coffee Co is an integrated coffee, tea, flavors, extracts, and ingredients solutions provider mainly in the United States. Additionally, it offers coffee sourcing, supply chain management, product development, roasting, packaging, and distribution services to retail, foodservice, restaurant, convenience store, travel center, non-commercial account, and hospitality industries around the world. The company's reportable segments are: Beverage Solutions and Sustainable Sourcing and Traceability. It generates maximum revenue from the Beverage Solutions segment, which offers beverage solutions, including coffee, tea, flavors, extracts, and ingredients. Geographically, the company generates maximum revenue from its business in the United States and the rest from other countries.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.